4 completed. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow oligoG CF-5-20: new trials by email Literature Review of oligoG CF-5-20 trials Research Report on oligoG CF-5-20
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection Alginate oligosaccharide, Placebo - Cystic Fibrosis, Burkholderia Infection | Phase 2 | Completed | AlgiPharma AS | 15 | 2015-02-01 | 2018-04-19 |
| A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis alginate oligosaccharide - Cystic Fibrosis | Phase 2 | Completed | AlgiPharma AS | 65 | 2014-10-01 | 2018-04-19 |
| A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis OligoG CF-5/20, Saline - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | AlgiPharma AS | 26 | 2011-05-01 | 2015-01-14 |
| Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis OligoG CF-5/20 - Cystic Fibrosis | Phase 1 | Completed | AlgiPharma AS | 26 | 2009-09-01 | 2016-03-23 |
Cystic Fibrosis (4) · Burkholderia Infections (1) · Digestive System Diseases (1) · Genetic Diseases, Inborn (1) · Lung Diseases (1) · Pancreatic Diseases (1) · Respiratory Tract Diseases (1)
AlgiPharma AS (4)
United Kingdom (3) · Germany (2) · Denmark (1) · Ireland (1) · Norway (1) · Sweden (1)
Martin Walshaw, MD (1) · Rainald Fischer, MD, PD (1) · Salvatore Febbraro (1) · Tacjana Pressler, PhD MD (1)